Pfizer-BioNTech launch trial of Omicron-targeted COVID-19 vaccine – CBC

Trial set to involve more than 1,400 U.S. volunteers

Jan 25, 2022

Pfizer and BioNTech said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

Banking on volunteers in the United States, the companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.

They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer-BioNTech vaccine three to six months earlier.

The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.

Read more: https://www.cbc.ca/news/health/omicron-vaccine-pfizer-1.6326547